🇺🇸 dolutegravir/abacavir/lamivudine in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug-Induced Liver Injury — 2 reports (18.18%)
  2. Acute Kidney Injury — 1 report (9.09%)
  3. Amblyopia — 1 report (9.09%)
  4. Bacillary Angiomatosis — 1 report (9.09%)
  5. Drug Interaction — 1 report (9.09%)
  6. Haemophagocytic Lymphohistiocytosis — 1 report (9.09%)
  7. Leukoencephalopathy — 1 report (9.09%)
  8. Mitochondrial Toxicity — 1 report (9.09%)
  9. Neurosyphilis — 1 report (9.09%)
  10. Peliosis Hepatis — 1 report (9.09%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is dolutegravir/abacavir/lamivudine approved in United States?

dolutegravir/abacavir/lamivudine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for dolutegravir/abacavir/lamivudine in United States?

University College Dublin is the originator. The local marketing authorisation holder may differ — check the official source linked above.